2008

 

2007

  • Cosmo awarded US patent for use of its MMX™ technology
  • UK Market launch of Mezavant XL™ by Shire plc on 05 November.
  • Licensing agreement with Ferring for Budesonide MMX™
  • US Market launch of Lialda™ by Shire plc on 19 March.
  • IPO on the Swiss Stock Exchange (SWX) on 12 March.
2006
  • FDA approval for the manufacturing of tablets to the USA.
  • Completion of 2.000 sq m plant in Lainate, Milan.
2005
  • Completion of first financing round of €20.4 million by Cosmo Holding S.p.A.
  • Lialda™/Mezavant™ Supply Agreement with Shire plc.
2004
  • Opening of an R&D laboratory in Catania, Italy.
2001
  • Lialda™/Mezavant™ globally out-licensed to Giuliani S.p.A./ Shire plc*.
1999
  • Filing of the first MMX™ Multi Matrix technology patent for the controlled release of tablets in the gastro-intestinal tract.
1998
  • Strategic decision to develop novel oral formulations of off-patent drugs to generate new patentable applications.
1997
  • Foundation of Cosmo S.p.A. by purchasing contract manufacturing unit in Lainate (Milan) from Parke Davis (now Pfizer Group).

*sublicensed

Back to top